Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/112035
Title: | Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease Treatment | Authors: | Olloquequi, Jordi Ettcheto, Miren Cano, Amanda Fortuna, A. Bicker, Joana Sánchez-López, Elena Paz, Cristian Ureña, Jesús Verdaguer, Ester Auladell, Carme Camins, Antoni |
Keywords: | neurodegeneration; cognitive enhancement; multi-target therapy | Issue Date: | 16-Sep-2023 | Publisher: | MDPI | Project: | This work was supported by funds from the Spanish Ministerio de Ciencia e Innovación (PID2021-123462OB-I00 to A.C. and C.A.; PID2021-122473OA-I00 to A. Cano) the Generalitat de Catalunya (2021 SGR 00288 to C.A.); CIBERNED (Grant CB06/05/2004 to A.C.), PI2021/03; Fundaçao para a Ciencia e Tecnologia (FCT), 127303; Instituto de Salud Carlos III (CD22/00125, A.Cano); Fundación ADEY grant under the program “Proyectos de Investigación en Salud 2023” (A.Cano) and Institut de Neurociències UB, CEX2021-001159-M. Jordi Olloquequi and Miren Ettcheto are Serra Húnter fellows. | Serial title, monograph or event: | International Journal of Molecular Sciences | Volume: | 24 | Issue: | 18 | Abstract: | Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds, the investigation of Licochalcone A's effects on the central nervous system and its potential application in Alzheimer's disease (AD) treatment have garnered significant interest. Studies have reported the neuroprotective effects of Lico-A, suggesting its potential as a multitarget compound. Lico-A acts as a PTP1B inhibitor, enhancing cognitive activity through the BDNF-TrkB pathway and exhibiting inhibitory effects on microglia activation, which enables mitigation of neuroinflammation. Moreover, Lico-A inhibits c-Jun N-terminal kinase 1, a key enzyme involved in tau phosphorylation, and modulates the brain insulin receptor, which plays a role in cognitive processes. Lico-A also acts as an acetylcholinesterase inhibitor, leading to increased levels of the neurotransmitter acetylcholine (Ach) in the brain. This mechanism enhances cognitive capacity in individuals with AD. Finally, Lico-A has shown the ability to reduce amyloid plaques, a hallmark of AD, and exhibits antioxidant properties by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant defense mechanisms. In the present review, we discuss the available findings analyzing the potential of Lico-A as a neuroprotective agent. Continued research on Lico-A holds promise for the development of novel treatments for cognitive disorders and neurodegenerative diseases, including AD. Further investigations into its multitarget action and elucidation of underlying mechanisms will contribute to our understanding of its therapeutic potential. | URI: | https://hdl.handle.net/10316/112035 | ISSN: | 1422-0067 | DOI: | 10.3390/ijms241814177 | Rights: | openAccess |
Appears in Collections: | I&D CIBIT - Artigos em Revistas Internacionais FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Licochalcone-A-A-Potential-Multitarget-Drug-for-Alzheimers-Disease-TreatmentInternational-Journal-of-Molecular-Sciences.pdf | 2.33 MB | Adobe PDF | View/Open |
Page view(s)
48
checked on Jul 17, 2024
Download(s)
33
checked on Jul 17, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License